EGFR and neoplasm: Additionally, 93% of the driving mutations identified in the tumor tissues are detected in the PE-cfDNA, including the changes in ALK, BRAF, EGFR, ERBB2, KRAS, NF1, PIK3CA, and RET, whereas only 62% of those are detected in the plasma cfDNA.